eurasia review Courtesy: Eurasia Review
25 February 2015

Examining the Gilead deal – Analysis

BY

Kunal Nathwani, Research Intern, Gateway House, has written an article analyzing the Gilead Licensing Agreement with seven Indian Pharmaceutical Companies. This article has been republished by Eurasia Review

Hindu Bizline Courtesy: The Hindu Business Line
25 February 2015

Tobin tax makes a lot of sense

BY

Rajrishi Singhal, Senior Geoeconomics Fellow, Gateway House, has written an article on the decision of Raghuram Rajan to insert one small restriction: henceforth all foreign portfolio investors investing in debt instruments — issued by government or private sector companies — have to hold on to their investments for a minimum of three years. This article has been republished by The Hindu Business Line

Copenhagen memorial Courtesy: Getty Images
24 February 2015

The fault-lines in Denmark

BY

The killings earlier this month in Copenhagen—manifestations of anti-free speech and anti-Jewish sentiments—were tragic and condemnable. Events such as these can only begin to be understood—not justified—within the growing contradictions of Scandinavian society

India voting finger Courtesy: electiontrends.in
24 February 2015

The quiet decline of anti-incumbency

BY

The last 25 years of Indian democracy have shown that anti-incumbency in state elections is on the decline. This is a positive trend because continuous terms will allow political parties to look beyond single-term policies and focus on long-term development

Gilead drugs Courtesy: media.licdn.com
19 February 2015

Examining the Gilead deal

BY

Widely heralded as a success that brought together U.S. and Indian pharma producers over a high-cost drug at affordable prices, the Gilead deal looked ideal. A closer examination shows there’s more to consider than just low costs before the deal can become a template